New Paradigm in Combination Therapy of siRNA with Chemotherapeutic Drugs towards Cancer Targeting

Chemotherapeutic drugs play a pivotal role in the treatment of cancer, but they have a negative impact on therapeutic outcomes. So, co-delivery strategies for administration of siRNA and chemotherapeutic drugs are gaining potential importance for treatment of many cancers. The ideal combination of chemotherapeutic drugs with siRNA is very crucial for producing the desirable anticancer effects.

Introduction

Cancer is a dynamic cellular process in which complex inter-play of cellular interactions and genetic alterations characterised by multiple gene mutations occur. The complexity of signaling pathways makes treatment of cancer difficult due to altered cellular mechanisms which cause cell death [1]. This calls for treatment modalities which can target the molecular mechanisms involved in cancer pathophysiology. Therefore, as a supplement to the existing therapy, combinatorial approaches are being implemented in the treatment of different types of cancers, wherein, along with chemotherapeutic agents, Small interfering RNA (siRNA) are being administered [2].In this line, the co-administration of chemotherapeutic drugs and small interfering RNA (siRNA) can act as a potential tool for the treatment of cancer and has attracted the attention of oncologists and researchers throughout the world.

The communication highlights and emphasizes on the various research outcomes which can be potentially used for the treatment of cancer.

RNA interference (RNAi) technology

RNA interference (RNAi) technology, as shown in Table 1 is being investigated as a possible strategy for developing highly targeted RNA based gene-silencing in cancer management. RNA interference (RNAi) inhibits expression of genes by binding to target messenger RNA (mRNA) and disrupts translation once they reach the cytoplasmic RNA-induced silencing complex (RISC)

Process of siRNA mediated RNA interference: The process initiates with cleaving of long double-stranded RNA (dsRNA) into siRNA or introducing exogenous siRNA into the cytoplasm with the Dicer enzyme complex. This is followed by binding of siRNAs to Argonaute 2 (AGO2) and the RNA-induced silencing complex (RISC).If complementarity of sequence is established between the RNA duplex packed onto RISC, AGO2 cleaves the passenger (sense) strand, resulting in active RISC containing the guide (antisense) strand. The siRNA guide strand helps to block the protein synthesis by binding to the target sites for direct mRNA cleavage (brought out via catalytic domain of AGO2) [9].

The rationale for selecting chemotherapeutic drug-siRNA pair for treatment of cancer

Combinatorial pairing of siRNAs and chemotherapeutic drug is very critical to the targeting of cellular pathways, multiple effects such as combination of anti-angiogenesis effect, or anti-proliferation effect, or reversal of MDR, or inhibition of metastasis (invasion) can be achieved. The suitable pair selection can thus provide many-fold increase in antitumor activity with the reduction of the dose [10]. The advantages of co-administration of siRNA with chemotherapeutic drugs which target various mechanisms for management of cancer have been demonstrated 

Significance for chemotherapeutic drugs and siRNA combination mechanisms

The success of the combination therapy along depends on the identification of the suitable gene target. The following genes have been targeted using this combinatorial therapy: (1) genes which play a role in cancer drug resistance (e.g., a gene encoding P-gp) (2) genes responsible for survival of tumors (e.g., gene encoding Bcl-2) (3) genes expressed selectively in cancerous tissues (e.g., gene encoding VEGF) [11]. Targeting of the distinct cellular signaling pathways, enhances the genetic hurdles for cancerous cells mutations resulting in retardation of the tumor adaptation system thereby improving therapeutic efficacy

Carrier systems for co-delivery of chemotherapeutic agents and siRNA

For the targeted and efficient delivery of nucleic –acid based drugs, suitable drug carriers are also required, as nucleic acids, including siRNAs, are water-soluble and negatively charged so it is difficult to deliver them through the cell membrane. For being delivered to the site of action for exerting their effect, they must escape in the intact form from endosomes and lysosomes. Furthermore, they must be protected against degradation by the endogenous enzymes and media along with the formulation excipients [12]. The extracellular barriers to RNAi-mediated siRNA delivery have been described in figure 3 and these barriers are being exploited by the researchers as potential delivery sites for the nucleic-acid based molecules. Herein, two types of delivery techniques: viral vectors-based and non-viral-based delivery techniques have been discussed.

Extracellular barriers to RNAi mediated siRNA therapy (A) Enzymatic degradation: Endonuclease degrades siRNA in blood circulation (B) Phagocytosis: The phagocyte cells (macrophages) removes siRNA from blood circulation via clearance through liver, lungs, and spleen (C) Tissue penetration: Repulsive interactions (due to anionic charge) between siRNA and plasma membrane of endothelial cells prevent internalisation of siRNA into cells, and are transported only by transcellular and paracellular transport mechanisms.

Nanocarrier chemotherapeutics-siRNA co-delivery system

Nanoparticles have the capacity to co-encapsulate chemotherapeutic drugs and siRNA and, they have been used to produce synergistic anticancer effect as shown in figure 4[13]. Various endocytotic mechanisms are available for the delivery of nanocarriers, like clathrin-based endocytosis, caveolae-based endocytosis, macropinocytosis, and additional clathrin and caveolae-independent endocytosis processes. Degradation of nanocarriersin the endosomes occurs by the lysosome (pH 4.8), facilitated by the acidic pH and degradative enzymes in the breakdown of these carriers and its payloads (e.g. siRNA). siRNAs need to escape the endosome during the loading period otherwise it may lead to lysosomal breakdown. Photochemical internalisation mechanism helps in endosomal escape of nanocarriers, as a result of the proton sponge effect, endosome membrane fusion, pore formation, and flip flop mechanism, among other strategies.

Conclusion

The shortfalls of the current cancer chemotherapy like sever adverse effects, drug resistance, and high dose of the drugs, RNA interference (RNAi) therapy is being explored as a promising targeted treatment strategy. Use of siRNA can be adopted as a potential method to down regulate the genes responsible for drug resistance and chemotherapeutic ineffectiveness. Co-delivery helps to increase the therapeutic efficacy by providing synergistic or additive effects thereby multi-drug resistance and the side effects. The combinatorial therapy also helps to target multiple pathways and regulatory proteins related to cancer cell growth, metastatic spread, and drug resistance. Despite considerable progress over the past few decades, there are still a number of obstacles to be overcome before siRNA and drugs can be successfully delivered together, so that it can be clinically translated.

Visit now: https://www.pharmafocusasia.com/articles/new-paradigm-in-combination-therapy-of-sirna-with-chemotherapeutic-drugs-towards-cancer-targeting